v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:        
Research and development $ 2,167,114 $ 1,713,973 $ 4,977,954 $ 3,305,115
General and administrative 2,289,649 2,394,912 4,051,368 4,747,009
Total operating expenses 4,456,763 4,108,885 9,029,322 8,052,124
Loss from operations (4,456,763) (4,108,885) (9,029,322) (8,052,124)
Other income, net 15,547 93,618 55,676 230,180
Change in fair value of convertible promissory notes (787,703) (787,703)
Net loss $ (5,228,919) $ (4,015,267) $ (9,761,349) $ (7,821,944)
Net loss available to common stockholders per share of common stock, basic [1] $ (9.09) $ (13.16) $ (18.09) $ (25.79)
Net loss available to common stockholders per share of common stock, diluted [1] $ (9.09) $ (13.16) $ (18.09) $ (25.79)
Weighted average number of shares used in calculating net loss per share, basic [1] 574,923 305,140 539,538 303,336
Weighted average number of shares used in calculating net loss per share, diluted [1] 574,923 305,140 539,538 303,336
[1] Retroactively restated for one-for-twenty-eight share consolidation on June 27, 2025.